Clinical Trials
68 trialsTargeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
National Cancer Institute (NCI)
Study of Chemotherapy Plus Ipatasertib for People With Solid Tumors With PTEN/AKT Mutations, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Comparing Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients With Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain After Earlier Stereotactic Radiosurgery
NRG Oncology
Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
National Cancer Institute (NCI)
Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer
National Cancer Institute (NCI)
Testing the Use of Nilotinib and Paclitaxel as a Treatment for Patients With Prior Taxane Treatment, A ComboMATCH Treatment Trial
National Cancer Institute (NCI)
Atezolizumab in Treating Patients With Cancer Following Adoptive Cell Transfer
National Cancer Institute (NCI)
Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma
National Cancer Institute (NCI)
Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
National Cancer Institute (NCI)
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer
National Cancer Institute (NCI)
Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial)
National Cancer Institute (NCI)
Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors
National Cancer Institute (NCI)
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
National Cancer Institute (NCI)
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
National Cancer Institute (NCI)
Studying TAK-243 in Patients With Advanced Cancer
National Cancer Institute (NCI)
Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients With Stomach or Other Solid Tumors
National Cancer Institute (NCI)
Testing How the Body Responds to the Drug CX-5461 (Pidnarulex) in Patients With Metastatic Solid Cancers
National Cancer Institute (NCI)
Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial
Fred Hutchinson Cancer Center
Testing Whether Cancers With Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study
National Cancer Institute (NCI)
Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NRG Oncology
Comparing Radiation Therapy to Usual Treatment for Patients With High-Risk Bone Metastases That Are Not Causing Pain, PREEMPT Trial
NRG Oncology
Trametinib and Navitoclax in Treating Patients With Advanced or Metastatic Solid Tumors
National Cancer Institute (NCI)
COD
National Cancer Institute (NCI)
SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial
Mayo Clinic
Comparison of Whole Body DWI to FDG PET
University of California, San Francisco
Application of ⁶⁸Ga-FXX489 (NNS309) PET/CT Imaging in Diagnosis of Tumor Diseases.
First Hospital of China Medical University
ACROP
Assistance Publique - Hôpitaux de Paris
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
National Cancer Institute (NCI)
MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers
Mayo Clinic
Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer
Fred Hutchinson Cancer Center
PNeoVCA
Mayo Clinic
Testing the Biological Effects of DS-8201a on Patients With Advanced Cancer
National Cancer Institute (NCI)
Study to Evaluate CD8 PET Imaging as a Marker of Immune Response to Stereotactic Body Radiation Therapy (ELIXR)
City of Hope Medical Center
Nivolumab and Ipilimumab in Treating Patients With HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
University of Washington
Imaging of Solid Tumors Using FAP-2286
University of California, San Francisco
Axatilimab in Combination With Retifanlimab and Paclitaxel for the Treatment of Patients With Advanced or Metastatic Solid Tumors
OHSU Knight Cancer Institute
STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma
City of Hope Medical Center
Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations
Fred Hutchinson Cancer Center
Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer
City of Hope Medical Center
Arginine and Whole Brain Radiation Therapy for the Treatment of Patients With Brain Metastases
Emory University
Biology-Guided Radiation Therapy for the Treatment of Patients With Bone Metastases
City of Hope Medical Center
NYM
Jonsson Comprehensive Cancer Center
Imaging of Solid Tumors Using 18F-TRX
University of California, San Francisco
Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer
National Cancer Institute (NCI)
Nab-Paclitaxel/STI-3031 Complex (AP160-Complex) for the Treatment of Advanced or Metastatic Solid Tumors
Mayo Clinic